Jeffrey Alan Sosman
#113,759
Most Influential Person Now
Jeffrey Alan Sosman's AcademicInfluence.com Rankings
Jeffrey Alan Sosmanphilosophy Degrees
Philosophy
#4858
World Rank
#7519
Historical Rank
Logic
#2235
World Rank
#3182
Historical Rank
Jeffrey Alan Sosmanbiology Degrees
Biology
#6459
World Rank
#9179
Historical Rank
Immunology
#337
World Rank
#350
Historical Rank
Download Badge
Philosophy Biology
Jeffrey Alan Sosman's Degrees
- Doctorate Medicine University of Chicago
- PhD Immunology University of Chicago
Why Is Jeffrey Alan Sosman Influential?
(Suggest an Edit or Addition)Jeffrey Alan Sosman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (4550)
- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. (2007) (3560)
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2010) (3502)
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. (2012) (2458)
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation (2010) (2097)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) (2096)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (2012) (2035)
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (2010) (1645)
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade. (2016) (1389)
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (2015) (1348)
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2016) (1323)
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) (2011) (1296)
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (2018) (1232)
- Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. (2010) (1228)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
- High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. (2001) (880)
- Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (2014) (835)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2017) (778)
- Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production (1997) (648)
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. (2005) (632)
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016) (618)
- Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance (2012) (614)
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. (2012) (610)
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis (2018) (518)
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. (2016) (513)
- Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. (2016) (495)
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance (2015) (482)
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (474)
- Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
- Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. (1997) (424)
- Featured Updates to the NCCN Guidelines (2019) (401)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. (2008) (395)
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade (2016) (370)
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. (2017) (367)
- Management of Immunotherapy-Related Toxicities, Version 1.2019. (2019) (363)
- Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. (2014) (354)
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy (2016) (352)
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. (2019) (349)
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. (2013) (346)
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019) (316)
- Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. (2005) (311)
- Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. (2003) (303)
- Phase I/II trial of tremelimumab in patients with metastatic melanoma. (2009) (294)
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (289)
- Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou (2008) (278)
- Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. (2015) (275)
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. (2016) (273)
- Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies (2016) (272)
- Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. (2008) (257)
- Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. (2016) (256)
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma (2011) (254)
- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (251)
- Functional analysis of human T cell subsets defined by monoclonal antibodies. I. Collaborative T-T interactions in the immunoregulation of B cell differentiation. (1980) (243)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. (2017) (233)
- Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. (2016) (231)
- Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. (2010) (227)
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. (2020) (217)
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. (2002) (210)
- High response rate to PD-1 blockade in desmoplastic melanomas (2017) (210)
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma (2006) (210)
- A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. (2013) (203)
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. (2002) (202)
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. (2017) (201)
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. (2017) (200)
- BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. (2012) (197)
- Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065)) (2017) (196)
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations (2018) (196)
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials (2012) (188)
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (2013) (185)
- Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses (2007) (184)
- Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis (1990) (183)
- BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. (2012) (182)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. (2014) (179)
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (2013) (174)
- Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition (2004) (170)
- Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021) (168)
- Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. (2012) (164)
- Immune Checkpoint Inhibitor Toxicity in 2018 (2018) (163)
- Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
- Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. (1988) (162)
- Melanoma, version 2.2016 clinical practice guidelines in oncology (2016) (161)
- A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma (2010) (154)
- The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition (2013) (149)
- Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. (1988) (144)
- Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group (2002) (143)
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies (2015) (143)
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (2011) (142)
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. (2020) (134)
- AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. (2008) (128)
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma (2014) (127)
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (2014) (125)
- Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. (1999) (123)
- Nivolumab in melanoma: latest evidence and clinical potential (2015) (123)
- Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival (2017) (122)
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. (2019) (122)
- Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. (1994) (121)
- Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. (1988) (121)
- A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. (2014) (120)
- Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. (2017) (118)
- Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer (2007) (116)
- A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. (2002) (109)
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). (2013) (109)
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. (2015) (107)
- Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. (2003) (106)
- Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials (2016) (106)
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis (2019) (105)
- A phase 2 trial of complete resection for stage IV melanoma (2011) (105)
- Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. (2008) (101)
- Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. (2014) (100)
- Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. (2012) (98)
- Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy (2013) (98)
- Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. (2017) (97)
- The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). (2010) (96)
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (96)
- Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. (2018) (96)
- Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. (1989) (93)
- Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies (2020) (93)
- Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). (2014) (92)
- Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. (2000) (91)
- Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) (2008) (91)
- Aberrant DNA methylation in malignant melanoma (2010) (90)
- Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease (2000) (90)
- Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (89)
- Melanoma: What do all the mutations mean? (2018) (89)
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center (2015) (88)
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
- Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition (2017) (86)
- Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. (1990) (86)
- Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative (2014) (86)
- Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma (2008) (84)
- Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. (2002) (84)
- A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance (2014) (83)
- Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. (1997) (83)
- The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study (2006) (83)
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. (2020) (80)
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. (2021) (79)
- The state of melanoma: challenges and opportunities (2016) (79)
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. (2015) (79)
- Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. (1978) (77)
- The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma (2019) (76)
- Therapeutic Advances and Treatment Options in Metastatic Melanoma. (2015) (74)
- Sunlight and reduced risk of cancer: is the real story vitamin D? (2005) (73)
- Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. (2015) (73)
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). (2013) (73)
- Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. (2007) (73)
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) (2012) (73)
- Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells (2015) (72)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- Past, Current, and Future of Immunotherapies for Prostate Cancer (2019) (70)
- Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. (1997) (69)
- Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. (2014) (69)
- Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. (2015) (66)
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. (2019) (65)
- Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide (2006) (61)
- A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. (2017) (61)
- Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. (2016) (60)
- Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). (2006) (60)
- Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction (2016) (59)
- Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies (2014) (59)
- Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). (2004) (59)
- A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, {+/-} dacarbazine (DTIC) in patients with metastatic melanoma (MM) (2005) (59)
- CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy (2019) (59)
- Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12 – Associated Toxicity and Interferon-g Production (1997) (57)
- Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma (2005) (57)
- Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. (2012) (57)
- Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. (2001) (57)
- Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. (2017) (57)
- B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma (2010) (56)
- A one-year survey of mold growth inside twelve homes. (1976) (56)
- Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia (2014) (56)
- Molecular Targets in Melanoma from Angiogenesis to Apoptosis (2006) (56)
- Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. (2013) (56)
- Kidney cancer, version 1.2021: Featured updates to the nccn guidelines (2020) (55)
- RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors (2012) (55)
- Functional analysis of human T cell subsets defined by monoclonal antibodies. III. Regulation of helper factor production by T cell subsets. (1981) (54)
- Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development (2005) (53)
- Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient. (1994) (53)
- Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431) (2008) (51)
- Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (51)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma (2009) (50)
- Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. (2011) (50)
- Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. (1998) (50)
- A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). (2006) (49)
- Update on the Targeted Therapy of Melanoma (2013) (49)
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors (2014) (49)
- Induction of human cytotoxic T lymphocytes specific for prostate‐specific antigen (1997) (49)
- Combination targeted therapy in advanced renal cell carcinoma (2009) (49)
- Kidney cancer: The cytokine working group experience (1986–2001) (2001) (48)
- A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. (2001) (47)
- Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). (2011) (47)
- Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). (2013) (46)
- Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. (1995) (45)
- A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets (2009) (44)
- Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers (2007) (44)
- Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab (2019) (43)
- Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. (1994) (42)
- A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. (1994) (42)
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy (2012) (42)
- Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial (2005) (42)
- Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. (2019) (41)
- Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure. (2017) (41)
- Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production. (2000) (41)
- Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer (2007) (40)
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma (2015) (40)
- Melacine®: an allogeneic melanoma tumor cell lysate vaccine (2003) (40)
- Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts). (2011) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma (2007) (39)
- Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. (1993) (39)
- Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). (2020) (38)
- 23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma (2009) (38)
- Melanoma from bench to bedside: meeting report from the 6th international melanoma congress (2010) (38)
- Clinical characterization of colitis arising from anti-PD-1 based therapy (2018) (37)
- CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (2016) (37)
- Immunoregulation by T cells. I. Characterization of the IEk-specific Lbd self-reactive T cell clone that helps, suppresses and contrasupresses B cell responses. (1986) (37)
- Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). (2017) (37)
- Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma (2017) (36)
- A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. (2010) (36)
- A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. (1995) (36)
- Specific recognition of human leukemic cells by allogeneic T cell lines. (1989) (35)
- Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. (1997) (35)
- A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. (2011) (34)
- Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer (2004) (34)
- Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. (2001) (34)
- Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. (2013) (33)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
- Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. (1997) (33)
- the influence of autologous lymphokine‐activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin‐2 (1990) (32)
- Kidney cancer: The cytokine working group experience (1986–2001) (2001) (32)
- Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. (2015) (32)
- Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. (1990) (31)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
- Oral health in oncology: impact of immunotherapy (2014) (31)
- Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib (2017) (31)
- PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. (2017) (31)
- Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. (1999) (30)
- 809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (30)
- 6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 (2009) (30)
- Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). (2017) (30)
- Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma (2007) (29)
- BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (29)
- Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. (1990) (28)
- In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. (1990) (28)
- Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial (2005) (28)
- Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. (2012) (27)
- Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). (2014) (27)
- When will melanoma vaccines be proven effective? (2004) (27)
- Integrated Genomic Analyses of Cutaneous T Cell Lymphomas Reveal the Molecular Bases for Disease Heterogeneity. (2021) (27)
- A phase I/II study of sequential interleukin-3 and granulocyte- macrophage colony-stimulating factor in myelodysplastic syndromes (1994) (26)
- Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy (2015) (26)
- Cancer Immunotherapies: Are They as Effective in the Elderly? (2017) (26)
- Non-viral precision T cell receptor replacement for personalized cell therapy (2022) (26)
- A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study (2013) (26)
- BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy (2018) (26)
- Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. (2020) (25)
- The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. (2018) (25)
- Novel Targeted Therapies for Metastatic Melanoma (2017) (25)
- Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities (2019) (25)
- PD-1/PD-L1 blockade in renal cell cancer (2017) (24)
- A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors (2017) (24)
- PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. (2009) (24)
- Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma (2019) (24)
- Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma (2016) (24)
- Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. (2016) (23)
- Emerging targeted therapies for melanoma (2016) (23)
- Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
- Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer (2002) (23)
- A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors (2016) (23)
- Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 (2022) (23)
- Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma. (1991) (22)
- Activation of Human T Cells Obtained Pre‐ and Post‐Interleukin‐2 (IL‐2) Therapy by Anti‐CD3 Monoclonal Antibody plus IL‐2: Implications for Combined In Vivo Treatment (1991) (22)
- Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (2012) (22)
- Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. (1989) (22)
- Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team (2015) (22)
- Responses to immune checkpoint inhibitors in nonagenarians (2016) (22)
- Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. (2020) (21)
- 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma (2015) (21)
- NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. (2020) (21)
- Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. (2006) (21)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (2012) (21)
- Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab (2016) (20)
- Myocarditis with Immune Checkpoint Blockade. (2017) (20)
- Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma (2019) (20)
- Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study (2007) (20)
- Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). (2015) (20)
- Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. (1989) (19)
- NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). (2013) (19)
- 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064) (2015) (19)
- whole-exome sequencing identifies (2016) (19)
- Interactions among human T cell subsets. (1981) (19)
- A multicenter characterization of hepatitis associated with immune checkpoint inhibitors (2021) (19)
- Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum (2016) (19)
- A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. (1995) (19)
- Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference (2006) (19)
- Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
- Severe eosinophilia and hepatocellular carcinoma: An unusual association (1995) (18)
- Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (2015) (18)
- Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy. (2003) (18)
- The State of Melanoma: Emergent Challenges and Opportunities (2021) (18)
- Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). (2017) (17)
- Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy (2016) (17)
- A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. (1994) (17)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
- Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. (2000) (17)
- Surgical resection for stage IV melanoma: A Southwest Oncology Group trial (S9430). (2006) (17)
- Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach (2014) (17)
- A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status (2017) (17)
- Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 (2010) (17)
- PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. (2010) (17)
- Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models (2015) (16)
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). (2016) (16)
- Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. (2012) (16)
- Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma (2019) (16)
- 1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA. (2014) (16)
- Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. (2016) (15)
- Trametinib in the treatment of melanoma (2015) (15)
- BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma (2022) (15)
- A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma (2007) (15)
- A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer? (2018) (15)
- A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. (2002) (15)
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy (2021) (15)
- Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation (1989) (15)
- A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS). (2010) (15)
- United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma. (2019) (15)
- Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma (2018) (14)
- Impact of MET expression on outcome in BRAFV600E/K advanced melanoma (2013) (14)
- Inside life of melanoma cell signaling, molecular insights, and therapeutic targets (2009) (14)
- The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape (2021) (14)
- A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). (2009) (14)
- Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors (2015) (13)
- FMelanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 23, 14-26 (2010) (13)
- Melanoma and other skin tumors (2012) (13)
- The graft-vs.-leukemia effect. Implications for post-marrow transplant antileukemia treatment. (1993) (13)
- Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. (2010) (13)
- Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. (1990) (13)
- Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors (2015) (13)
- Cutaneous Melanoma , Version 2 . 2019 (2019) (13)
- Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. (2004) (13)
- Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206 (2007) (13)
- First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. (2017) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. (2012) (13)
- Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma (2016) (12)
- Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone (2016) (12)
- Health care utilization and steroid‐refractory toxicities from immune checkpoint inhibitors (2020) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential. (2014) (12)
- A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma (2005) (12)
- ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma (2015) (12)
- A phase II trial of interleukin‐2 in myelodysplastic syndromes (1998) (12)
- Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. (2004) (12)
- Improved methods for RNAseq-based alternative splicing analysis (2021) (11)
- Tumor-infiltrating lymphocytes and interleukin-2 in melanomas. (1989) (11)
- Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) (2022) (11)
- Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. (2015) (11)
- The cellular immunotherapy of cancer: current and potential uses of interleukin-2. (1989) (11)
- CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC) (2015) (11)
- Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy (2020) (11)
- The graft versus leukemia effect: possible mechanisms and clinical significance to the biologic therapy of leukemia. (1991) (10)
- Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies. (2013) (10)
- Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial (1999) (10)
- Phase II study of erlotinib given daily for patients with metastatic melanoma (MM). (2006) (10)
- Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily × 7 every 3 weeks. (2004) (10)
- Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies (2003) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors (2011) (10)
- The graft versus leukemia (GVL) effect following bone marrow transplantation (BMT): A review of laboratory and clinical data (1987) (10)
- Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM). (2016) (10)
- Addition of interleukin-2in vitro augments detection of lymphokine-activated killer activity generatedin vivo (2005) (10)
- Melanoma driver mutations and immune therapy (2016) (10)
- Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling. (2016) (10)
- Vemurafenib: B-raf kinase inhibitor, oncolytic (2011) (9)
- Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
- Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
- A Phase IA/IB Trial of Anti‐CD3 Murine Monoclonal Antibody plus Low‐Dose Continuous‐Infusion Interleukin‐2 in Advanced Cancer Patients (1995) (9)
- Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035 (2004) (9)
- BRAF and MEK inhibitor therapy eliminates Nestin‐expressing melanoma cells in human tumors (2018) (9)
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis (2021) (8)
- A Phase II, Randomized, Open-Label Study Evaluating the Antitumor Activity of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha v Beta 3 (avb3) Integrin, ±Dacarbazine (DTIC) in Patients With Metastatic Melanoma (MM) (2005) (8)
- Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase I Study. (2021) (8)
- A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma (2016) (8)
- The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. (1989) (8)
- Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors. (2013) (8)
- Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. (2011) (8)
- Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508 (2008) (8)
- A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy. (2013) (8)
- Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). (2013) (8)
- Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival (2014) (8)
- Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma (2022) (8)
- Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. (2016) (7)
- Improving outcomes in patients with advanced renal cell carcinoma (2008) (7)
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. (2015) (7)
- Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716). (2018) (7)
- TRF requirements for in vitro PFC responses to SRBC and R36a. I. TRF is distinct from IL 2 but indistinguishable from polyclonal BCSF. (1984) (7)
- High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. (1995) (7)
- Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 (2013) (6)
- A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts) (2005) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma (2017) (6)
- Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). (2005) (6)
- Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (6)
- Patient‐centered engagement and symptom/toxicity monitoring in the new era of tumor next‐generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms (2019) (6)
- Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). (2007) (5)
- CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment (2016) (5)
- A randomized trial of PSA-peptide based, specific active immunotherapy in HLA-A2+ patients with prostate cancer: Comparison of two different vaccination strategies (2005) (5)
- A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. (2010) (5)
- 1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL. (2014) (5)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. (2022) (5)
- First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. (2011) (5)
- Abstract 2855: Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma (2015) (5)
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors (2019) (5)
- Reporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply (2018) (5)
- Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group Trial S0438. (2010) (5)
- Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study (2007) (5)
- Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. (2018) (5)
- Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616). (2018) (4)
- Targeting multiple genetic aberrations in isolated tumor cells by spectral fluorescence in situ hybridization. (2002) (4)
- Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial (2023) (4)
- Interleukin 10‐induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production (2000) (4)
- Biological drug duo delivers one-two tumor punch (2003) (4)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B). (2021) (4)
- 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) (2015) (4)
- First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts) (2007) (4)
- "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes. (1989) (4)
- Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. (2022) (4)
- New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. (2012) (4)
- Stereotactic Radiosurgery Plus Whole Brain Radiation Therapy vs. Stereotactic Radiosurgery Alone in the Treatment of Brain Metastases from Malignant Melanoma (2010) (4)
- 4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers (2007) (4)
- Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial (2015) (4)
- Dacarbazine induced acute myeloid leukemia in melanoma. (2009) (4)
- An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL). (2013) (4)
- Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics. (2015) (4)
- Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. (2017) (4)
- Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma (2008) (4)
- A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. (1995) (4)
- Abstract 853: Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients (2016) (4)
- Melanoma and a Headache. Diagnosis: Hypophysitis. (2015) (3)
- Novel insights into the pathogenesis and treatment of NRAS mutant melanoma (2021) (3)
- Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy with Checkpoint Inhibitors (2017) (3)
- BRAFV600E-mutant melanoma presenting with cardiac involvement. (2014) (3)
- Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy (2020) (3)
- Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial (2021) (3)
- Immunomodulatory effects of high‐dose and low‐dose interferon α2b in patients with high‐risk resected melanoma (2002) (3)
- Ipilimumab in acral melanoma: A retrospective review. (2014) (3)
- Re: Sun exposure and mortality from melanoma (multiple letters) [1] (2005) (3)
- MYOCARDITIS AND RHABDOMYOLYSIS INCIDENCE WITH IMMUNE CHECKPOINT INHIBITORS (2017) (3)
- Overview: cellular immunotherapy of cancer. (1987) (3)
- MEK + CDK4 a regimen for non-BRAF V6000 melanoma (2015) (3)
- Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma. (2019) (3)
- A Phase 1 dose-escalation trial of the c-MET inhibitor ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumors (2010) (3)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
- Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (2)
- Leptomeningeal metastases: the future is now (2022) (2)
- Molecular characterization of immune-related severe adverse events (irSAE). (2017) (2)
- CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer (2000) (2)
- 1224PDAnalysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002 (2017) (2)
- Melanoma BRAF Fusions—Response (2014) (2)
- Scientific rationale for immunotherapy in lymphoma and predictors of response (2017) (2)
- Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results (2012) (2)
- Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. (2018) (2)
- Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors (2012) (2)
- A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report. (2022) (2)
- The role of autoreactive T-cell lines in the restoration of the immune response to sheep red blood cells in C57Bl/6-lpr/lpr mice. (1989) (2)
- Kidney Cancer, Version 3.2022 (2021) (2)
- 701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) (2021) (2)
- Erratum: 'Improving outcomes in patients with advanced renal cell carcinoma' (Expert Review of Anticancer Therapy (2008) vol. 8 (3) (481-490)) (2008) (1)
- Adverse Events Associated With Immune Checkpoint Inhibitors-Reply. (2019) (1)
- A phase II trial of piroxantrone in disseminated malignant melanoma (2007) (1)
- First-line ipilimumab bests placebo in trial using DTIC: Commentary (2011) (1)
- Clinical Utility of BRAF-Targeted Therapy in Melanoma (2015) (1)
- Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors (2022) (1)
- Anti-PD-1 in patients with advanced malignancies and baseline organ dysfunction. (2016) (1)
- Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). (2016) (1)
- Melanoma: Does Sequencing Really Matter? (2022) (1)
- Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy (2022) (1)
- Lymphokine-activated Killer Activity Induced by in Vivo Interleukin 2 Therapy : Predominant Role for Lymphocytes with Increased Expression of CD 2 and Leul 9 Antigens but Negative Expression of CD 16 Antigens 1 (2006) (1)
- BRAF inhibitor gives striking survival advantage in BRIM-3: Commentary (2011) (1)
- Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma. (2019) (1)
- Adding T-VEC to Ipilimumab for Advanced Melanoma (2016) (1)
- Abstract PR04: BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. (2013) (1)
- A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study. (1995) (1)
- Phase II trial of O6-benzylguanine (O6BG) and BCNU in patients with advanced melanoma (2004) (1)
- VEGF-Trap (V-T) overcomes defects in dendritic cell (DC) differentiation without improvement in antigen-specific immune responses (2007) (1)
- hase II Study of Autologous Transplantation with nterleukin-2 – Incubated Peripheral Blood Stem Cells nd Posttransplantation Interleukin-2 in Relapsed r Refractory Non-Hodgkin Lymphoma (2004) (1)
- 7004 ORAL Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma (2007) (1)
- Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. (2010) (1)
- The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 (2021) (1)
- Emerging growth factor receptor antagonists for the treatment of advanced melanoma (2017) (1)
- Abstract A26: Integrated epigenomic profiling reveals widespread demethylation in melanoma, and reveals aberrant CSF-1 receptor expression as a regulator of malignant growth and invasion inhibited by PLX3397 (2013) (1)
- 23 Clinical Status of RAF/MEK Inhibitors (2012) (1)
- Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors. (2015) (1)
- Cytokines and immunological monitoring. (1997) (1)
- SP 123 Overcoming drug resistance in melanoma (2011) (0)
- Resistance to Anti–PD-1 Therapy in Melanoma Patients (2016) (0)
- Cells Increase IDO 1 Expression in GlioblastomaandContribute toDecreasedPatient Survival (2017) (0)
- Proactive assessment better than watch and wait for stage I melanoma. Comment (2005) (0)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
- IMST-39. IDO1 IS PROGNOSTIC FOR GLIOBLASTOMA PATIENT SURVIVAL AND CENTRALLY CORRELATES WITH POTENTLY IMMUNOSUPPRESSIVE MEDIATORS (2016) (0)
- Immune reaction portends melanoma response to CTLA-4 blockade. Comment (2005) (0)
- leukemia class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with Antigen-specific recognition of autologous leukemia cells and allogeneic (2009) (0)
- Marine-derived compound may benefit sarcoma subtypes (2005) (0)
- The Pharmacokinetics and Safety of ABT-751 , a Novel , Orally Bioavailable SulfonamideAntimitotic Agent : Results of a Phase 1 Study (2006) (0)
- Advances in the Management and Treatment of Metastatic Melanoma (2012) (0)
- Antigen-reactive t cell clones from xid mice help t15+ anti-phosphorylcholine pfc responses. Abstr. (1983) (0)
- Abstract 1885: Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition (2016) (0)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. (2023) (0)
- NCCN: Continuing Education (2019) (0)
- Sunitinib highly efficacious in imatinib-resistant/intolerant GIST: Comment (2006) (0)
- Bisbee: A proteomics validated analysis package for detecting differential splicing, identifying splice outliers, and predicting splice event protein effects (2020) (0)
- Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. (2017) (0)
- What Tx is your first choice for metastatic BRAF+ melanoma? (2011) (0)
- Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies (2023) (0)
- with combined dabrafenib and trametinib in a phase 1/2 clinical trial (2014) (0)
- Sorafenib trials report mixed results in advanced melanoma: Commentary (2007) (0)
- The MEK inhibitor trametinib for the treatment of advanced melanoma (2014) (0)
- The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 (2021) (0)
- Reply to O. Devlin et al. (2023) (0)
- Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM) (2012) (0)
- Title: Contribution of Beta-HPV Infection and UV-Damage to Rapid-onset Cutaneous Squamous Cell Carcinoma during BRAF-inhibition Therapy Running Title: Beta-HPV and UV-damage in cutaneous SCC during BRAF Therapy (2015) (0)
- Novel peptide vaccine breaks cycle of negative trials: Commentary (2009) (0)
- Phase II trial of O6-benzylguanine (O6BG) and BCNU in patients with advanced melanoma. (2004) (0)
- PLX4032 draws 70% response in metastatic melanoma: Commentary (2009) (0)
- 1478 A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells (2022) (0)
- The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
- cells crossreactive with determinants present on unrelated nonleukemic Evidence for HLA-D restricted determinants on leukemic cells that are Specific recognition of human leukemic cells by allogeneic T cells: II. (2016) (0)
- Wnt signaling may play a tumor-suppressor role in high-grade undifferentiated sarcomas: Comment (2006) (0)
- Molecular Pathways Molecular Pathways : Targeting NRAS in Melanoma and Acute Myelogenous Leukemia (2014) (0)
- Neurological Applications of Belzutifan in von Hippel Lindau Disease. (2022) (0)
- Combining Ipilimumab with a Vaccine for Advanced Melanoma (2016) (0)
- Abstract PR06: Integrated epigenomic profiling reveals widespread demethylation in melanoma and reveals CSF-1 Receptor as an aberrant regulator of malignant growth and invasion (2015) (0)
- A novel high-dose chemotherapy regimen of cyclophosphamide, mitoxantrone, and carboplatin with autologous bone marrow transplantation: Activity in refractory gynecologic malignancies (1991) (0)
- Melanoma-specific MHC-II expression to predict response to α-PD-1 therapy. (2015) (0)
- Isolated limb perfusion appears beneficial for in-transit melanoma: Comment (2006) (0)
- Signal transduction inhibitor BAY 43-9006 plus chemo promising in metastatic melanoma (2005) (0)
- Abstract PR03: CD8+ T-cell distribution and immunomodulator expression in BRAF-mutant melanoma affect the response to BRAF inhibitor and chemotherapy (2015) (0)
- Phase II trial of interleukin 2, interferon α, and 5-fluorouracil in metastatic renal cell cancer (2002) (0)
- Sorafenib-dacarbazine combination shows activity in metastatic melanoma. Comment (2005) (0)
- Abstract 2920: Characterizing human melanoma treatment responsein vivousing single-cell mass cytometry analysis of longitudinal tumor biopsies (2017) (0)
- Pegylated interferon alfa-2b aids relapse-free survival: Commentary (2007) (0)
- RESPONSE: Re: Sun Exposure and Mortality From Melanoma (2005) (0)
- Highlights from the literature (2019) (0)
- Advancements in unresectable melanoma: a multidisciplinary perspective. (2016) (0)
- chromosome-bearing (Ph1+) human leukemia lines can also Allogeneic T-cell clones able to selectively destroy Philadelphia (2009) (0)
- Clinical correlates of response to anti-PD-1 (aPD1)-based therapy in patients (pts) with metastatic melanoma (MM). (2017) (0)
- Targeted therapies becoming a reality in melanoma: Commentary (2009) (0)
- Outcomes in BRAFV600e-Mutant Melanoma Brain Metastases Managed with Radiosurgery: A Multi-Institutional Assessment of Craniotomy Mitigation (2018) (0)
- Abstract 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition (2017) (0)
- A Time to Ignore "No Meat, No Treat". (2019) (0)
- UROLOGICAL ONCOLOGY: RENAL, URETERAL AND RETROPERITONEAL TUMORS (2008) (0)
- Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial (2003) (0)
- Experimental melanoma therapies fail to improve survival: Comment (2006) (0)
- Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors. (2017) (0)
- BEAM trial: Bevacizumab survival gains are short of significant: Commentary (2009) (0)
- Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma (2017) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Regional hyperthermia delays sarcoma progression: Commentary (2007) (0)
- Abstract B12: Synergistic anticancer activity of Aurora A kinase and MDM2 antagonists in melanoma (2015) (0)
- Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer 1 (2006) (0)
- PD-1 Blockade for Advanced Merkel-Cell Carcinoma (2016) (0)
- Abstract IA13: Treatment of non-V600-mutated BRAF melanoma: A role for combination MEK and CDK4/6 inhibition (2015) (0)
- Truncated interferon therapy may be comparable: Commentary (2007) (0)
- Ensemble computational analysis and systems immune monitoring reveal a double negative T cell subset enriched in melanoma tumors following dabrafenib and trametinib (2017) (0)
- Melanoma from bench to bedside: Meeting report from the 6th international melanoma congress (Pigment Cell and Melanoma Research (2010) 23, (14-26 )) (2010) (0)
- The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
- The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 (2023) (0)
- Total Body Irradiation for Advanced Melanoma (2016) (0)
- Abstract 2942: NRAS mutation as a predictor of response to immune-based therapies in patients with metastatic melanoma (2014) (0)
- Abstract 5102: Identifying targets for melanoma therapy: Biological and clinical implications of BRAF L597 mutants (2012) (0)
- Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF (2012) (0)
- Targeted Therapy in Advanced Melanoma (2019) (0)
- Back to the drawing board in Melanoma vaccine effort: Commentary (2007) (0)
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
- Abstract IA15: Treatment of non-V600-mutated BRAF melanoma: A role for combination MEK and CDK4/6 inhibition. (2015) (0)
- Ipilimumab Adjuvant Therapy for Stage III Melanoma (2016) (0)
- Abstract LB-428: RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors (2012) (0)
- Abstract IA24: Are there nonimmune targets in the BRAFV600 WT melanoma patient? (2020) (0)
- Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma (2023) (0)
- GM-CSF, vaccine, sorafenib show little benefit in trials: Commentary (2010) (0)
- B-Raf-Mutated Melanoma (2020) (0)
- Abstract A064: IDO1 expression stratifies glioblastoma patient survival and correlates with dominantly immunosuppressive pathways (2016) (0)
- 802 An electronic health record-based approach to identify and characterize patients with immune checkpoint inhibitor-associated arthritis (2021) (0)
- Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy. (2023) (0)
- Ganglioside vaccine is associated with worse survival: Commentary (2008) (0)
- Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma (2019) (0)
- What is the first-line treatment of choice for metastatic BRAF-mutant melanoma? (2012) (0)
- Cyclooxygenase inhibition and response to anti-PD1/L1 in advanced melanoma. (2016) (0)
- Landmark study backs ipilimumab in advanced disease: Commentary (2010) (0)
- Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) (2023) (0)
- Photodynamic therapy of human malignant melanoma xenografts in athymic nude mice. (2018) (0)
- 270 The Impact of a Tissue Acquisition Program On Research in Molecular Targeted Therapy of Melanoma (2012) (0)
- Il-2 plus g-csf as a mobilization regimen in advanced breast cancer patients receiving high dose chemotherapy: marked expansion of activated t and nk cells with enhanced cytolyt1c activity within the autograft, without compromise of the hematologic engraftment (1998) (0)
- Ulcerated primary melanomas respond to adjuvant interferon: Commentary (2009) (0)
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis (2019) (0)
- 90 Tumor infiltrating leukocyte subpopulations as a biomarker of response and resistance to targeted therapy in patients with BRAF mutation-positive metastatic melanoma (2014) (0)
- Adjuvant doxorubicin/ifosfamide disappoints in sarcoma: Commentary (2007) (0)
- PD1 regulates T cell exhaustion phenotypes and disease aggressiveness in CTCL (2021) (0)
- 312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition (2020) (0)
- More stage III disease anticipated with AJCC changes: Commentary (2009) (0)
- Trametinib, dabrafenib strike at BRAF-mutant disease: Commentary (2012) (0)
- Abstract 3389: Integrated genomic analyses reveal frequentTERTaberrations in acral melanoma (2017) (0)
- Characterizing toxicities, body composition, and health-related quality of life (HRQoL) among long-term survivors treated with anti-PD-1. (2020) (0)
- Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). (2016) (0)
- Detection of Copy NumberAlterations in Metastatic Melanoma by a DNAFluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization : A Southwest Oncology Group Study ( S 9431 ) (2008) (0)
- IMMU-66. IDO1 EXPRESSION STRATIFIES PATIENT SURVIVAL AND IS REGULATED BY TUMOR INFILTRATING T CELLS IN HUMAN GLIOBLASTOMA (2017) (0)
- Pembrolizumab for Advanced Melanoma (2016) (0)
- Isolation and characterization of an autoreactive T cell clone which regulates differentiation of activated B cells (1984) (0)
- Abstract 2515: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and BRAF-inhibitor resistance (2018) (0)
- Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A). (2023) (0)
- Abstract 5126: The link between therapy-induced senescence and anti-tumor immune microenvironment in melanoma (2016) (0)
- Trabectedin: Redefining response with benefit in myxoid liposarcomas: Comment (2006) (0)
- 162 Resistance to RAF Inhibitors Due to RAS-independent Dimerization of BRAF(V600E) Splicing Variants (2012) (0)
- CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy (2019) (0)
- How I Treat Patients with BRAF Wild-Type Metastatic Melanoma (2013) (0)
- Subtype-specific differences in the genomic landscape of cutaneous T cell lymphomas (2021) (0)
- Natural Killer Cells Activated by Interleukin 2 Treatment in Vivo Respond to Interleukin 2 Primarily through the p75 Receptor and Maintain the p55 (TAC) Negative Phenotype1 (2006) (0)
- Renal cell cancer (2006) (0)
- Notice of retraction: "Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development" (BJUI, Volume 96, Issue 3, pages 286 – 290). (2012) (0)
- Highlights from the literature (2013) (0)
- PD325901 well tolerated in advanced melanoma. Comment (2005) (0)
- Natural Killer Cells Activated by Interleukin 2 Treatment in Vivo Respond to Interleukin 2 Primarily through the p 75 Receptor and Maintain the p 55 ( TAC ) Negative Phenotype 1 (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jeffrey Alan Sosman?
Jeffrey Alan Sosman is affiliated with the following schools:
